Top 10 Contract Development and Manufacturing Organizations 2026
Alex Philippidis analyzes the top CDMOs this year, noting a bright future as biopharma is expected to increase their reliance on CDMOs in coming years despite rising costs for their services. Which companies made the top 10 list? Check out the list to find out.
Next 10 U.S. Biopharma Clusters
For the first time, GEN‘s Alex Philippidis examines the top regions and top states just below the 10 largest regions for life sciences activity, as the field looks beyond the East and West Coasts for growth.
Top 10 Best-Selling Drugs 2026
Thanks to booming sales of blockbuster obesity and diabetes treatments, the amount that Americans spent on prescription drugs this year is on track to surpass $1 trillion. Total aggregate value of the drugs generating the highest sales in 2025 jumped 21.5% vs. 2024, and more than doubled from a decade ago.
GEN Digital Edition
Access the latest issue of GEN and browse the archive of back issues when you subscribe to our digital edition.
Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies
In this GEN webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study.
Emily Gaither
Engineer III, Downstream Purification
Thermo Fisher Scientific
Podcast
Touching Base
Touching Base is the dynamic podcast series from the editors of GEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what’s now and next. Start listening today!
Stay up to date with the lasted episodes of Touching Base by subscribing to the GEN Podcast Newsletter
Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue
StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit
